1. Home
  2. GBTG vs CELC Comparison

GBTG vs CELC Comparison

Compare GBTG & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Global Business Travel Group Inc.

GBTG

Global Business Travel Group Inc.

HOLD

Current Price

$5.80

Market Cap

2.9B

Sector

Technology

ML Signal

HOLD

Logo Celcuity Inc.

CELC

Celcuity Inc.

HOLD

Current Price

$119.58

Market Cap

3.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GBTG
CELC
Founded
2014
2011
Country
United Kingdom
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Medical Specialities
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.9B
3.1B
IPO Year
2020
2017

Fundamental Metrics

Financial Performance
Metric
GBTG
CELC
Price
$5.80
$119.58
Analyst Decision
Buy
Strong Buy
Analyst Count
6
9
Target Price
$8.92
$112.56
AVG Volume (30 Days)
1.1M
669.5K
Earning Date
05-11-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
173.33
N/A
EPS
0.22
N/A
Revenue
$2,718,000,000.00
N/A
Revenue This Year
$21.78
N/A
Revenue Next Year
$4.29
$720.19
P/E Ratio
$26.34
N/A
Revenue Growth
12.17
N/A
52 Week Low
$4.96
$9.64
52 Week High
$8.64
$129.09

Technical Indicators

Market Signals
Indicator
GBTG
CELC
Relative Strength Index (RSI) 52.41 51.74
Support Level $5.28 $99.38
Resistance Level $5.88 N/A
Average True Range (ATR) 0.19 6.84
MACD -0.01 -0.51
Stochastic Oscillator 43.03 58.91

Price Performance

Historical Comparison
GBTG
CELC

About GBTG Global Business Travel Group Inc.

Global Business Travel Group Inc operates as a business-to-business travel platform. It is engaged in providing software and services to manage travel, expenses, and meetings and events for companies of all sizes. The company is engaged in building the marketplace in B2B travel to deliver unrivaled choice, value, and experiences. It also provides business travel solutions, simplified travel management, and business consulting services. Further, The company generates revenue in two ways that involves fees and other revenues relating to processing and servicing travel transactions received from clients and travel suppliers and revenues for the provision of products and professional services not directly related to transactions received from clients, travel suppliers and Network Partners.

About CELC Celcuity Inc.

Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.

Share on Social Networks: